Trevi TherapeuticsTRVI
TRVI
About: Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Employees: 33
0
Funds holding %
of 7,429 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
113% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 30
70% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 23
66% more call options, than puts
Call options by funds: $5.27M | Put options by funds: $3.18M
13% more capital invested
Capital invested by funds: $554M [Q1] → $626M (+$72M) [Q2]
10% more funds holding
Funds holding: 137 [Q1] → 151 (+14) [Q2]
6.47% more ownership
Funds ownership: 91.16% [Q1] → 97.62% (+6.47%) [Q2]
13% less funds holding in top 10
Funds holding in top 10: 8 [Q1] → 7 (-1) [Q2]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$18
147%
upside
Avg. target
$22
207%
upside
High target
$27
271%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
Morgan Stanley Judah Frommer | 147%upside $18 | Overweight Initiated | 21 Aug 2025 |
Raymond James Ryan Deschner | 271%upside $27 | Strong Buy Maintained | 8 Aug 2025 |
Needham Serge Belanger | 202%upside $22 | Buy Maintained | 8 Aug 2025 |
Cantor Fitzgerald Josh Schimmer | 243%upside $25 | Overweight Initiated | 1 Jul 2025 |
D. Boral Capital Jason Kolbert | 188%upside $21 | Buy Maintained | 2 Jun 2025 |
Financial journalist opinion
Based on 4 articles about TRVI published over the past 30 days
Neutral
Seeking Alpha
2 weeks ago
Trevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call Transcript
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants g - Corporate Participant e - Corporate Participant Farrell Simon - Chief Commercial Officer James V. Cassella - Chief Development Officer Jennifer L.
Neutral
PRNewsWire
2 weeks ago
Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF Closed $115 million underwritten offering with expected cash runway into 2029 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn.
Neutral
PRNewsWire
3 weeks ago
Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn.
Neutral
PRNewsWire
4 weeks ago
Trevi Therapeutics to Participate in Upcoming August Conferences
NEW HAVEN, Conn. , July 29, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in August.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know
The mean of analysts' price targets for Trevi Therapeutics (TRVI) points to a 231.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
PRNewsWire
1 month ago
Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism
NEW HAVEN, Conn. , July 1, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, and Lisa Delfini, Chief Financial Officer, will be attending Leerink Partners Therapeutics Forum: I&I and Metabolism, held from July 8-9 in Boston, Massachusetts.
Neutral
GlobeNewsWire
2 months ago
TRVI STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Trevi Therapeutics, Inc. (NASDAQ: TRVI) and Encourages Long-Term Investors to Contact the Firm
PHILADELPHIA, June 26, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Trevi Therapeutics, Inc. (NASDAQ: TRVI) (“Trevi”) on behalf of the company's long-term investors.
Neutral
PRNewsWire
2 months ago
Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
NEW HAVEN, Conn. , June 5, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced the closing of its previously announced underwritten public offering of 20,010,000 shares of its common stock at a public offering price of $5.75 per share, which includes 2,610,000 additional shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the public offering at the public offering price, less underwriting discounts and commissions.
Neutral
PRNewsWire
2 months ago
Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
NEW HAVEN, Conn. , June 3, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced the pricing of its previously announced underwritten public offering of 17,400,000 shares of its common stock at a public offering price of $5.75 per share, for total proceeds of $100 million, before deducting underwriting discounts and commissions and expenses payable by Trevi.
Neutral
PRNewsWire
2 months ago
Trevi Therapeutics Announces Proposed Public Offering of Common Stock
NEW HAVEN, Conn. , June 2, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock.
Charts implemented using Lightweight Charts™